Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region

Antiviral Research

Volumn 116, Issue , 2015, Pages 10-16

  Sarrazin, Christoph ^a   Lathouwers, Erkki ^b   Peeters, Monika ^b   Daems, Bjorn ^b   Buelens, Annemie ^b   Witek, James ^c   Wyckmans, Yves ^b   Fevery, Bart ^b   Verbinnen, Thierry ^b   Ghys, Anne ^b   Schlag, Michael ^d   Baldini, Alessandra ^e   De Meyer, Sandra ^b   Lenz, Oliver ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d Janssen Cilag Pharma GmbH   (Austria)

^e Laboratoire Janssen Cilag   (France)

Author keywords

Hepatitis C; NS3 4A protease; Prevalence; Q80K polymorphism; Simeprevir; Virology

Indexed keywords

SIMEPREVIR; TELAPREVIR; ANTIVIRUS AGENT; NS3 PROTEIN, HEPATITIS C VIRUS; OLIGOPEPTIDE; VIRUS PROTEIN;

ARTICLE; ENZYME POLYMORPHISM; EUROPEAN; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; META ANALYSIS; NORTH AMERICAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION RESEARCH; PRIORITY JOURNAL; DNA SEQUENCE; EPIDEMIOLOGY; EUROPE; FEMALE; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MALE; NORTH AMERICA; PREVALENCE; SINGLE NUCLEOTIDE POLYMORPHISM; VIROLOGY;

HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; EUROPE; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; NORTH AMERICA; OLIGOPEPTIDES; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; SEQUENCE ANALYSIS, DNA; SIMEPREVIR; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84922318694     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.01.003     Document Type: Article

References (47)

1. AASLD/IDSA Recommendations for Testing, Managing, and Treating Hepatitis C. Available at: http://www.hcvguidelines.org/full-report-view. Date accessed: 16th September 2014.
2. N. Afdhal, K.R. Reddy, D.R. Nelson, E. Lawitz, S.C. Gordon, E. Schiff, R. Nahass, R. Ghalib, N. Gitlin, R. Herring, J. Lalezari, Z.H. Younes, P.J. Pockros, A.M. Di Bisceglie, S. Arora, G.M. Subramanian, Y. Zhu, H. Dvory-Sobol, J.C. Yang, P.S. Pang, W.T. Symonds, J.G. McHutchison, A.J. Muir, M. Sulkowski, P. Kwo ION-2 Investigators Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N. Engl. J. Med. 370 2014 1483 1493
3. A. Bae, S.C. Sun, X. Qi, X. Chen, K. Ku, A. Worth, K.A. Wong, J. Harris, M.D. Miller, and H. Mo Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors Antimicrob. Agents Chemother. 54 2010 5288 5297
4. R.J. Barnard, J.A. Howe, R.A. Ogert, S. Zeuzem, F. Poordad, S.C. Gordon, R. Ralston, X. Tong, V. Sniukiene, J. Strizki, D. Ryan, J. Long, P. Qiu, C.A. Brass, J. Albrecht, M. Burroughs, S. Vuocolo, and D.J. Hazuda Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies Virology 444 2013 329 336
5. D.J. Bartels, J.C. Sullivan, E.Z. Zhang, A.M. Tigges, J.L. Dorrian, S. De Meyer, D. Takemoto, E. Dondero, A.D. Kwong, G. Picchio, and T.L. Kieffer Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment J. Virol. 87 2013 1544 1553
6. K.L. Berger, I. Triki, M. Cartier, M. Marquis, M.J. Massariol, W.O. Böcher, Y. Datsenko, G. Steinmann, J. Scherer, J.O. Stern, and G. Kukolj Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir Antimicrob. Agents Chemother. 58 2014 698 705
7. M. Buti, K. Agarwal, Y. Horsmans, W. Sievert, E. Janczewska, S. Zeuzem, L. Nyberg, R.S. Brown Jr., C. Hézode, M. Rizzetto, R. Paraná, S. De Meyer, R. De Masi, D. Luo, K. Bertelsen, and J. Witek Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C Gastroenterology 146 2014 744 753
8. S. Chlabicz, R. Flisiak, O. Kowalczuk, A. Grzeszczuk, B. Pytel-Krolczuk, D. Prokopowicz, and L. Chyczewski Changing HCV genotypes distribution in Poland - relation to source and time of infection J. Clin. Virol. 42 2008 156 159
9. Clinicaltrials.gov. An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation (REPLACE). Available at: http://clinicaltrials.gov/ct2/show/NCT01571583?term=VX-950HPC3006&rank=1. Date accessed: 19th August 2014.
10. A. De Luca, S. Di Giambenedetto, M. Prosperi, A. Lo Presti, C. Torti, C. Caudai, I. Vicenti, F. Saladini, P. Almi, P. Grima, P. Blanc, M. Fabbiani, B. Rossetti, R. Gagliardini, M. Ciccozzi, and M. Zazzi Two distinct HCV genotype 1a clades: geographical distribution and association with natural resistance mutations to HCV NS3/4A inhibitors Antiviral Ther. 18 Suppl. 1 2013 A47 (Abstract 39)
11. S. De Meyer, I. Dierynck, A. Ghys, M. Beumont, B. Daems, B. Van Baelen, J.C. Sullivan, D.J. Bartels, T.L. Kieffer, S. Zeuzem, and G. Picchio Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial Hepatology 56 2012 2106 2115
12. I. Dierynck, K. Thys, A. Ghys, J.C. Sullivan, T.L. Kieffer, J. Aerssens, G. Picchio, and S. De Meyer Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3-4A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE study J. Infect. Dis. 210 2014 1871 1880
13. Dieterich, D., Bacon, B.R., Flamm, S.L., Kowdley, K.V., Milligan, S., Tsai, N., Younossi, Z., Lawitz, E. et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Presented at AASLD 2014 Abstract 46. Available at: http://www.natap.org/2014/AASLD/AASLD-09.htm. EASL Recommendations on Treatment of Hepatitis C 2014. Available at: http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C.pdf. Date accessed: 16th September 2014.
14. Fevery, B., Thys, K., Van Eygen, V., Verbinnen, T., Van Rossem, E., Picchio, G., De Meyer, S., Lenz, O., 2014. EASL International Liver Congress 2014. Poster 220. Available at: http://www.natap.org/2014/EASL/EASL-62.htm.
15. X. Forns, E. Lawitz, S. Zeuzem, E. Gane, J.P. Bronowicki, P. Andreone, A. Horban, A. Brown, M. Peeters, O. Lenz, S. Ouwerkerk-Mahadevan, J. Scott, G. De La Rosa, R. Kalmeijer, R. Sinha, and M. Beumont-Mauviel Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial Gastroenterology 146 2014 1669 1679
16. M.W. Fried, M. Buti, G.J. Dore, R. Flisiak, P. Ferenci, I. Jacobson, P. Marcellin, M. Manns, I. Nikitin, F. Poordad, M. Sherman, S. Zeuzem, J. Scott, L. Gilles, O. Lenz, M. Peeters, V. Sekar, G. De Smedt, and M. Beumont-Mauviel Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study Hepatology 58 2013 1918 1929
17. S. Gaudieri, A. Rauch, K. Pfafferott, E. Barnes, W. Cheng, G. McCaughan, N. Shackel, G.P. Jeffrey, L. Mollison, R. Baker, H. Furrer, H.F. Günthard, E. Freitas, I. Humphreys, P. Klenerman, S. Mallal, I. James, S. Roberts, D. Nolan, and M. Lucas Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy Hepatology 49 2009 1069 1082
18. J.J. Germer, D.W. Majewski, M. Rosser, A. Thompson, P.S. Mitchell, T.F. Smith, S. Elagin, and J.D. Yao Evaluation of the TRUGENE HCV 5′NC genotyping kit with the new Gene Librarian module 3.1.2 for genotyping of hepatitis C virus from clinical specimens J. Clin. Microbiol. 41 2003 4855 4857
19. M. Grigorescu Romanian Society of Gastroenterology and Hepatology HCV genotype 1 is almost exclusively present in Romanian patients with chronic hepatitis C J. Gastrointest. Liver Dis. 18 2009 45 50
20. C. Hedskog, B. Doehle, K. Chodavarapu, V. Gontcharova, J. Crespo Garcia, R. De Knegt, J.P. Drenth, J.G. McHutchison, D. Brainard, L.M. Stamm, M.D. Miller, E. Svarovskaia, and H. Mo Characterization of hepatitis C virus inter-genotypic recombinant strains and associated virologic response to sofosbuvir/ribavirin Hepatology 2014 10.1002/hep.27361
21. C. Hézode, N. Forestier, G. Dusheiko, P. Ferenci, S. Pol, T. Goeser, J.P. Bronowicki, M. Bourlière, S. Gharakhanian, L. Bengtsson, L. McNair, S. George, T. Kieffer, A. Kwong, R.S. Kauffman, J. Alam, J.M. Pawlotsky, S. Zeuzem PROVE2 Study Team Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N. Engl. J. Med. 360 2009 1839 1850
22. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, N.H. Bzowej, P. Marcellin, A.J. Muir, P. Ferenci, R. Flisiak, J. George, M. Rizzetto, D. Shouval, R. Sola, R.A. Terg, E.M. Yoshida, N. Adda, L. Bengtsson, A.J. Sankoh, T.L. Kieffer, S. George, R.S. Kauffman, S. Zeuzem ADVANCE Study Team Telaprevir for previously untreated chronic hepatitis C virus infection N. Engl. J. Med. 364 2011 2405 2416
23. I.M. Jacobson, G.J. Dore, G.R. Foster, M.W. Fried, M. Radu, V.V. Rafalsky, L. Moroz, A. Craxi, M. Peeters, O. Lenz, S. Ouwerkerk-Mahadevan, G. De La Rosa, R. Kalmeijer, J. Scott, R. Sinha, and M. Beumont-Mauviel Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial Lancet 384 2014 403 413
24. Jacobson, I.M, Dore, G.J., Foster, G.R., Fried, M., Manns, M., Marcellin, P., Poordad, F., Affonso de Araujo, E.S., Peeters, M., Lenz, O., Ouwerkerk-Mahadevan, S., De La Rosa, G., Kalmeijer, R., Sinha, R., Beumont-Mauviel, M., 2013. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve patients: efficacy in difficult-to-treat patient sub-populations in the QUEST-1 and 2 Phase III trials. In: 64rd Annual Meeting of the American Association for the Study of Liver Diseases. Poster presentation. Available at: http://www.natap.org/2014/APASL/APASL-19.htm. Date accessed: 16th September 2014.
25. T. Kuntzen, J. Timm, A. Berical, N. Lennon, A.M. Berlin, S.K. Young, B. Lee, D. Heckerman, J. Carlson, L.L. Reyor, M. Kleyman, C.M. McMahon, C. Birch, J. Schulze Zur Wiesch, T. Ledlie, M. Koehrsen, C. Kodira, A.D. Roberts, G.M. Lauer, H.R. Rosen, F. Bihl, A. Cerny, U. Spengler, Z. Liu, A.Y. Kim, Y. Xing, A. Schneidewind, M.A. Madey, J.F. Fleckenstein, V.M. Park, J.E. Galagan, C. Nusbaum, B.D. Walker, G.V. Lake-Bakaar, E.S. Daar, I.M. Jacobson, E.D. Gomperts, B.R. Edlin, S.M. Donfield, R.T. Chung, A.H. Talal, T. Marion, B.W. Birren, M.R. Henn, and T.M. Allen Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients Hepatology 48 2008 1769 1778
26. D. Koletzki, T. Pattery, B. Fevery, L. Vanhooren, and L.J. Stuyver Amplification and sequencing of the hepatitis C virus NS3/4A protease and the NS5B polymerase regions for genotypic resistance detection of clinical isolates of subtypes 1a and 1b Methods Mol. Biol. 1030 2013 137 149
27. E. Lawitz, M.S. Sulkowski, R. Ghalib, M. Rodriguez-Torres, Z.M. Younossi, A. Corregidor, E. DeJesus, B. Pearlman, M. Rabinovitz, N. Gitlin, J.K. Lim, P.J. Pockros, J.D. Scott, B. Fevery, T. Lambrecht, S. Ouwerkerk-Mahadevan, K. Callewaert, W.T. Symonds, G. Picchio, K.L. Lindsay, M. Beumont, and I.M. Jacobson Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study Lancet 384 2014 1756 1765
28. McCloskey, R.M., Liang, R.H., Joy, J.B., Krajden, M., Montaner, J.S.G., Harrigan, P.H., Poon, A.F.Y., 2014. Global origin and transmission of hepatitis C virus NS3 Q80K polymorphism. [Epub ahead of print].
29. V. Morel, G. Duverlie, and E. Brochot Patients eligible for treatment with simeprevir in a French center J. Clin. Virol. 61 2014 149 151
30. Lenz, O., Verbinnen, T., Fevery, B., Tambuyzer, L., Vijgen, L., Peeters, M., Buelens A., Beumont-Mauviel M., Picchio G, De Meyer S., 2014. Virology analyses of simeprevir in Phase 2b and 3 studies. EASL International Liver Congress 2014. Poster 221. Available at: http://www.natap.org/2014/EASL/EASL-63.htm. Date accessed: 16th September 2014.
31. M. Manns, P. Marcellin, F. Poordad, E.S. de Araujo, M. Buti, Y. Horsmans, E. Janczewska, F. Villamil, J. Scott, M. Peeters, O. Lenz, S. Ouwerkerk-Mahadevan, G. De La Rosa, R. Kalmeijer, R. Sinha, and M. Beumont-Mauviel Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial Lancet 384 2014 414 426
32. P. Marcellin, X. Forns, T. Goeser, P. Ferenci, F. Nevens, G. Carosi, J.P. Drenth, L. Serfaty, K. De Backer, R. Van Heeswijk, D. Luo, G. Picchio, and M. Beumont Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C Gastroenterology 140 2011 459 468
33. Moreno, C., Hézode, C., Marcellin, P., Bourgeois, S., Francque, S., Samuel, D., Zoulim, F., Grange, J.-D., Lenz, O., Ouwerkerk-Mahadevan, S., Peeters, M., Beumont-Mauviel, M., Jessner, W. Once-daily simeprevir (TMC435) with peginterferon/ribavirin in treatment-naïve or treatment-experienced chronic HCV genotype 4-infected patients: final results of a Phase III trial. 2014 EASL International Liver Congress 2014. Poster P1319. Abstract available at: http://www.professionalabstracts.com/ilc2014/planner/index.php?go=abstract&action=abstract-show&absno=3712&ILC2014=8d20f7okaone2akbib0ks0efauotgv13. Date accessed: 16th September 2014.
34. J.G. McHutchison, M.P. Manns, A.J. Muir, N.A. Terrault, I.M. Jacobson, N.H. Afdhal, E.J. Heathcote, S. Zeuzem, H.W. Reesink, J. Garg, M. Bsharat, S. George, R.S. Kauffman, N. Adda, and A.M. Di Bisceglie Telaprevir for previously treated chronic HCV infection N. Engl. J. Med. 362 2010 1292 1303
35. F. McPhee, J. Friborg, S. Levine, C. Chen, P. Falk, F. Yu, D. Hernandez, M.S. Lee, S. Chaniewski, A.K. Sheaffer, and C. Pasquinelli Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir Antimicrob. Agents Chemother. 56 2012 3670 3681
36. B.E. Pickett, R. Striker, and E.J. Lefkowitz Evidence for separation of HCV subtype 1a into two distinct clades J. Viral. Hepat. 18 2011 608 618
37. T. Pilot-Matias, R. Tripathi, D. Cohen, I. Gaultier, T. Dekhtyar, L. Lu, T. Reisch, M. Irvin, T. Hopkins, R. Pithawalla, T. Middleton, T. Ng, K. McDaniel, Y.S. Or, R. Menon, D. Kempf, A. Molla, and C. Collins In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450 Antimicrob. Agents Chemother. 2014 Epub ahead of print
38. Reddy, K.R., Zeuzem, S., Zoulim, F., Weiland, O., Horban, A., Stanciu, C., Villamil, F., Andreone, P., George, J., Dammers, E., Fu, M., Kurland, D., Lenz, O., Ouwerkerk-Mahadevan, S., Verbinnen, T., Jessner, W. A Phase III randomised, double-blind study to evaluate the efficacy, safety and tolerability of simeprevir vs telaprevir in combination with pegylated interferon and ribavirin in chronic hepatitis C virus genotype 1 treatment-experienced patients: the ATTAIN study. Asian Pacific Association for the Study of the Liver 2014. Oral Presentation. Available at: http://www.natap.org/2014/APASL/APASL-20.htm. Date accessed: 16th September 2014.
39. K.E. Sherman, S.L. Flamm, N.H. Afdhal, D.R. Nelson, M.S. Sulkowski, G.T. Everson, M.W. Fried, M. Adler, H.W. Reesink, M. Martin, A.J. Sankoh, N. Adda, R.S. Kauffman, S. George, C.I. Wright, F. Poordad ILLUMINATE Study Team Response-guided telaprevir combination treatment for hepatitis C virus infection N. Engl. J. Med. 365 2011 1014 1024
40. S. Shafran Telaprevir activity is unaffected by the Q80K polymorphism in hepatitis C virus genotype 1a Can. J. Gastroenterol. Hepatol. 28 2014 510
41. Simeprevir Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002777/WC500167867.pdf. Date accessed 16th September 2014.
42. E. Stelzl, C. van der Meer, R. Gouw, M. Beld, M. Grahovac, E. Marth, and H.H. Kessler Determination of the hepatitis C virus subtype: comparison of sequencing and reverse hybridization assays Clin. Chem. Lab. Med. 45 2007 167 170
43. Sulkowski, M.S., Vargas, H.S., Di Bisceglie, A.M., Kuo, A., Reddy, K.R., Lim, J.K., Morelli, M., Feld, J.J., Brown, R.S., Frazier, L.M., Fried, M.W., Nelson, D.R., Jacobson, I.M., 2014. Safety and efficacy of sofosbuvir (SOF) in combination with simeprevir (SIM) + Ribavirin (RBV) in patients with genotype 1: interim results of a prospective, observational study. Presented at AASLD 2014. Abstract 955. Available at: http://www.natap.org/2014/AASLD/AASLD-10.htm.
44. M.S. Sulkowski, D.F. Gardiner, M. Rodriguez-Torres, K.R. Reddy, T. Hassanein, I. Jacobson, E. Lawitz, A.S. Lok, F. Hinestrosa, P.J. Thuluvath, H. Schwartz, D.R. Nelson, G.T. Everson, T. Eley, M. Wind-Rotolo, S.-P. Huang, M. Gao, D. Hernandez, F. McPhee, D. Sherman, R. Hindes, W. Symonds, C. Pasquinelli, and D.M. Grasela Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N. Engl. J. Med. 370 2014 211 221
45. Verbinnen, T., Fevery, B., Vijgen, L., Picchio, G., De Meyer, S., Lenz, O., 2014. Phenotypic characterisation of genotype 1 hepatitis C NS3 protease variants from clinical studies with simeprevir. Presented at the International Workshop on Antiviral Drug Resistance, Berlin, Germany.
46. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, S. Roberts, R. Focaccia, Z. Younossi, G.R. Foster, A. Horban, P. Ferenci, F. Nevens, B. Müllhaupt, P. Pockros, R. Terg, D. Shouval, B. van Hoek, O. Weiland, R. Van Heeswijk, S. De Meyer, D. Luo, G. Boogaerts, R. Polo, G. Picchio, M. Beumont REALIZE Study Team Telaprevir for retreatment of HCV infection N. Engl. J. Med. 364 2011 2417 2428
47. S. Zeuzem, T. Berg, E. Gane, P. Ferenci, G.R. Foster, M.W. Fried, C. Hezode, G.M. Hirschfield, I. Jacobson, I. Nikitin, P.J. Pockros, F. Poordad, J. Scott, O. Lenz, M. Peeters, V. Sekar, G. De Smedt, R. Sinha, and M. Beumont-Mauviel Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial Gastroenterology 146 2014 430 441